NCT02702947 is a Phase 4 clinical trial of Prunus domestica extract in BPH, sponsored by Chemical Resources.

Who is sponsoring NCT02702947?

NCT02702947 is sponsored by Chemical Resources.

What drugs are being tested in NCT02702947?

Interventions in NCT02702947: Prunus domestica extract.

Is NCT02702947 still recruiting?

NCT02702947 is currently completed. Last updated 1 November 2016.

Last reviewed 2016-11-01 · How we verify

NCT02702947

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EFFICACY EVALUATION OF PRUNUS DOMESTICA EXTRACT ON BENIGN PROSTATE HYPERPLASIA (BPH): An Add on Study

Completed Phase 4 Last updated 1 November 2016

What this trial tests

Phase 4 trial testing Prunus domestica extract in BPH in 160 participants. Completed in 1 September 2016.

Timeline

1 March 2014

Primary endpoint
1 May 2016

1 September 2016

Quick facts

Lead sponsor	Chemical Resources
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Enrollment	160
Start date	1 March 2014
Primary completion	1 May 2016
Estimated completion	1 September 2016
Sites	1 location across India

Drugs / interventions tested

Prunus domestica extract

Conditions studied

BPH — all drugs for BPH →

Sponsor

Chemical Resources — full company profile →

Who can join

Adults 40 to 65, male only, with BPH. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Reduction in prostate volume
Time frame: 12 weeks

Sponsor's own description

Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate Prunus domestica bark contains three groups of active constituents: phytosterols (including beta-sitosterol), pentacyclic triterpenoids (including ursolic and oleaic acids) and ferulic esters of long-chain fatty alcohols (including ferulic esters of docosanol and tetracosanol). The phytosterols, particularly beta-sitosterol, are found in numerous plants and are anti-inflammatory, inhibiting the synthesis of prostaglandins. Beta-sitosterol has been shown to be useful in cases of BPH by helping to reduce the normally elevated levels of prostaglandins in these patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for BPH

Currently open trials in the same condition.

NCT07115147 — Blue Diode Laser Vaporization for BPH · NA · recruiting
NCT05401032 — Proof-of-concept Study to Evaluate the Safety and Efficacy of Tryptophan in Patients with BPH. · Phase 2 · recruiting
NCT05719220 — Effect of Group Preoperative Pelvic Floor Training for HoLEP · recruiting
NCT05620784 — Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP · Phase 3 · recruiting
NCT05330520 — Long Term Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Pat · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02702947 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chemical Resources
Last refreshed: 1 November 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02702947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing